SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Scinai Immunotherapeutics Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026

$0.75−0.00 (-0.32%)

Close on Oct 19, 2026

Community

Notes and questions about Scinai Immunotherapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Scinai Immunotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Aug 21, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SCNI.

Operating margin-575.3% · median -4762.2%

Net margin-633.6% · median -4366.4%

Advertisement
300 × 250